MA40306A1 - Méthodes et formulations pour le traitement de pathologies oculaires vasculaires - Google Patents

Méthodes et formulations pour le traitement de pathologies oculaires vasculaires

Info

Publication number
MA40306A1
MA40306A1 MA40306A MA40306A MA40306A1 MA 40306 A1 MA40306 A1 MA 40306A1 MA 40306 A MA40306 A MA 40306A MA 40306 A MA40306 A MA 40306A MA 40306 A1 MA40306 A1 MA 40306A1
Authority
MA
Morocco
Prior art keywords
methods
formulations
treatment
ocular pathologies
vascular ocular
Prior art date
Application number
MA40306A
Other languages
English (en)
Inventor
Daniel Dix
Ivan B Lobov
Jingtai Cao
Robert L Vitti
Kristine A Erickson
Karen W Chu
Stanley J Wiegand
Saurabh Wadhwa
Kenneth S Graham
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA40306A1 publication Critical patent/MA40306A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

La présente invention concerne des méthodes de traitement, de prévention ou de réduction de la gravité d'une pathologie oculaire. Les méthodes de la présente invention consistent à administrer à un sujet le nécessitant, une composition thérapeutique comprenant un inhibiteur de l'angiopoïétine-2 (ang-2) tel qu'un anticorps anti-ang-2 en combinaison avec un antagoniste du facteur de croissance endothéliale vasculaire (vegf) (
MA40306A 2014-11-25 2015-11-19 Méthodes et formulations pour le traitement de pathologies oculaires vasculaires MA40306A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462084003P 2014-11-25 2014-11-25
US201562147232P 2015-04-14 2015-04-14
US14/943,490 US20160144025A1 (en) 2014-11-25 2015-11-17 Methods and formulations for treating vascular eye diseases
PCT/US2015/061543 WO2016085750A1 (fr) 2014-11-25 2015-11-19 Méthodes et formulations pour le traitement de pathologies oculaires vasculaires

Publications (1)

Publication Number Publication Date
MA40306A1 true MA40306A1 (fr) 2019-03-29

Family

ID=56009149

Family Applications (2)

Application Number Title Priority Date Filing Date
MA041028A MA41028A (fr) 2014-11-25 2015-11-18 Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA40306A MA40306A1 (fr) 2014-11-25 2015-11-19 Méthodes et formulations pour le traitement de pathologies oculaires vasculaires

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA041028A MA41028A (fr) 2014-11-25 2015-11-18 Méthodes et formulations pour le traitement de pathologies oculaires vasculaires

Country Status (18)

Country Link
US (3) US20160144025A1 (fr)
EP (1) EP3224278A4 (fr)
JP (2) JP2017536414A (fr)
KR (1) KR20170087950A (fr)
CN (1) CN107001457A (fr)
AU (1) AU2015353838A1 (fr)
BR (1) BR112017009807A2 (fr)
CA (1) CA2968522A1 (fr)
CL (1) CL2017001188A1 (fr)
CO (1) CO2017004715A2 (fr)
EA (1) EA201791168A1 (fr)
IL (1) IL252159B (fr)
MA (2) MA41028A (fr)
MX (1) MX2017006129A (fr)
PE (1) PE20170900A1 (fr)
PH (1) PH12017500834A1 (fr)
SG (1) SG11201703609UA (fr)
WO (1) WO2016085750A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2850830A1 (fr) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methodes de traitement du syndrome de fuite vasculaire et du cancer
US9822367B2 (en) 2013-02-21 2017-11-21 Rsem, Limited Partnership Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
EP3116503A4 (fr) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Inhibiteurs de hptp-bêta
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP3273840B1 (fr) * 2015-03-26 2024-07-17 Eyekor, LLC Analyse d'images
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
US20200056186A1 (en) 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
US20190300607A1 (en) * 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
AU2018266324B2 (en) * 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
KR102584848B1 (ko) * 2017-08-18 2023-10-04 리제너론 파마슈티칼스 인코포레이티드 샘플 매트릭스에서 단백질 변이체를 분석하기 위한 이미지 모세관 등전 집속
AU2018375398C1 (en) * 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
EP3730126B1 (fr) * 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Composition liquide comprenant un antagoniste du vegf
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2019154776A1 (fr) * 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Traitement de maladies ophthalmologiques
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019173767A1 (fr) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Formulations aqueuses stables d'aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
CN112912104A (zh) * 2018-08-17 2021-06-04 三钰生物科技股份有限公司 抗血管新生融合蛋白及其用途
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
CN109598628B (zh) * 2018-11-30 2022-09-20 平安医疗健康管理股份有限公司 医保欺诈行为的识别方法、装置、设备及可读存储介质
AU2019407063B2 (en) 2018-12-18 2024-07-04 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2020223209A1 (fr) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Activateurs de tie -2 ciblant le canal de schlemm
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
CN110423281B (zh) * 2019-07-31 2021-04-30 成都金唯科生物科技有限公司 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2021220138A1 (fr) * 2020-04-29 2021-11-04 Novartis Ag Système et procédé mis en œuvre par ordinateur pour évaluer un niveau d'activité d'une maladie ou d'un état dans l'œil d'un patient
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
WO2021259200A1 (fr) * 2020-06-22 2021-12-30 信达生物制药(苏州)有限公司 Anticorps anti-ang-2 et son utilisation
JP2023535933A (ja) * 2020-07-24 2023-08-22 パンジェン バイオテック インコーポレイテッド 眼科用液状組成物
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2005072772A1 (fr) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
SI2944306T1 (sl) * 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2665956A1 (fr) * 2009-05-07 2010-11-07 Samir Patel Traitement combine pour des maladies oculaires
SG176202A1 (en) * 2009-05-28 2011-12-29 Glaxo Group Ltd Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
US20120189635A1 (en) * 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
LT3495387T (lt) * 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2014089111A1 (fr) * 2012-12-05 2014-06-12 Novartis Ag Compositions et procédés pour des anticorps ciblant epo
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
BR112016000282A2 (pt) * 2013-07-11 2017-12-12 Novartis Ag uso de antagonista de vegf em tratamento de retinopatia da prematuridade
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US9914769B2 (en) * 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment

Also Published As

Publication number Publication date
EA201791168A1 (ru) 2017-09-29
EP3224278A4 (fr) 2018-07-11
CN107001457A (zh) 2017-08-01
CO2017004715A2 (es) 2017-09-20
AU2015353838A1 (en) 2017-06-08
JP2017536414A (ja) 2017-12-07
WO2016085750A1 (fr) 2016-06-02
PE20170900A1 (es) 2017-07-12
MA41028A (fr) 2017-10-03
KR20170087950A (ko) 2017-07-31
US20160144025A1 (en) 2016-05-26
BR112017009807A2 (pt) 2018-02-27
CA2968522A1 (fr) 2016-06-02
EP3224278A1 (fr) 2017-10-04
PH12017500834A1 (en) 2017-10-30
CL2017001188A1 (es) 2017-11-24
US20190117767A1 (en) 2019-04-25
JP2021046431A (ja) 2021-03-25
US11071780B2 (en) 2021-07-27
SG11201703609UA (en) 2017-06-29
IL252159A0 (en) 2017-07-31
MX2017006129A (es) 2018-04-10
US20170080086A1 (en) 2017-03-23
IL252159B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MA41013B1 (fr) Compositions comprenant des souches bactériennes
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
MA44322A (fr) Compositions comprenant des souches bactériennes
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA53937B1 (fr) Compositions comprenant des souches bactériennes
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA44890A (fr) Compositions comprenant des souches bactériennes
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
MA42560A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
CO6602152A2 (es) En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga.
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA50441A (fr) Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
NZ785158A (en) Topical cyclosporine-containing formulations and uses thereof
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
FR3019465B1 (fr) Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen